8-K: Rezolute Presents Phase 3 sunRIZE Study Data

Rezolute announced expanded analyses from its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism, showing consistent glycemic improvements and high OLE participation.

Summary

• Rezolute presented additional data from its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI) at the Pediatric Endocrine Society (PES) 2026 Annual Meeting.
• The presentation included expanded analyses from pre-specified and post-hoc Continuous Glucose Monitoring (CGM)-based outcomes.
• While the secondary endpoint (% time in hypoglycemia by CGM) did not achieve statistical significance at Week 24, larger and nominally statistically significant glycemic improvements were observed during the maintenance dosing phase.
• These improvements included significant reductions in average daily percent time in hypoglycemia and weekly hypoglycemia events, and significant increases in exposure to normoglycemia (AUC 70-180 mg/dL) and average blood glucose levels.
• The open-label extension (OLE) phase shows high participation (57 of 59 completers) with continued glycemic benefit and reduction/discontinuation of background standard of care (SOC) therapies, with many patients now on ersodetug monotherapy.
• The FDA acknowledged challenges with the primary endpoint (SMBG-based events) and requested broader study data for evaluation.
• Rezolute is confident in ersodetug's potential to transform HI treatment and seeks alignment with the FDA for approval.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While the primary endpoint miss is a significant negative, the company is presenting strong secondary and OLE data, and has FDA engagement, suggesting a potential path forward.

Positives

• Demonstrated clinically relevant and nominally statistically significant reductions in average daily percent time in hypoglycemia (>50% in FAS, ~60-80% in PPS).
• Showed clinically relevant and nominally statistically significant reductions in average weekly hypoglycemia events (~50-65% in FAS, ~50-80% in PPS).
• Observed clinically relevant and nominally statistically significant increases in average daily AUC 70 to 180 mg/dL (exposure to normoglycemia) (~25-50% in FAS and PPS).
• Achieved clinically relevant and nominally statistically significant increases in average blood glucose (~10-15 mg/dL in FAS and PPS).
• High participation and retention in the open-label extension (OLE) phase (57 of 59 completers), indicating patient and physician confidence.
• Continued glycemic benefit observed in the OLE phase, with a significant reduction and/or discontinuation of background standard of care (SOC) therapies.
• A significant number of patients are now receiving ersodetug as monotherapy in the OLE phase.
• The FDA acknowledged challenges with the primary endpoint and requested broader data for comprehensive evaluation.

Negatives

• The study did not meet its primary endpoint, which assessed the change in average weekly hypoglycemia events by self-monitored blood glucose (SMBG) compared to placebo.
• The reductions observed in the primary endpoint were not statistically significant.
• The secondary endpoint (% time in hypoglycemia by CGM) did not achieve statistical significance at the Week 24/End of Treatment evaluation window.

Risks

• The Company's ability to predict results or the actual results of its plans or strategies is inherently uncertain.
• Actual results may differ materially from anticipated results.
• Readers are cautioned not to place undue reliance on forward-looking statements.
• Important factors that may cause differences include any other factors discussed in the Company's filings with the SEC, including Risk Factors in Form 10-K and 10-Q.

Future Outlook

Rezolute is seeking alignment with the FDA on an acceptable path to approval for ersodetug in congenital hyperinsulinism, based on the presented data and ongoing OLE observations.

Management Comments

• "We are pleased to highlight that deeper analyses of the sunRIZE outcomes and ongoing observations from the extension phase of the study consistently indicate evidence of target engagement, drug activity, and the potential for meaningful therapeutic benefit from ersodetug."
• "These results underscore our confidence in the potential of ersodetug to transform the HI treatment landscape and embolden our mission to achieve alignment with FDA on an acceptable path to approval in this indication, so that we can keep delivering ersodetug to patients and families living with congenital HI."

Industry Context

StockSavvy.ai notes that Rezolute's announcement regarding ersodetug for congenital hyperinsulinism comes at a time when the rare disease therapeutics sector continues to see significant investment and focus on unmet medical needs, particularly in pediatric conditions. The company's strategy to leverage CGM data and OLE observations to address FDA concerns on primary endpoints is a common approach in navigating complex regulatory pathways for novel therapies.

Related Party Transactions

• Diva D. De Len-Crutchlow, M.D., M.S.C.E., is a paid consultant to Rezolute Inc., and served as the site Principal Investigator for the Phase 3 sunRIZE study.

Stakeholder Impact

• Patients and families living with congenital hyperinsulinism may benefit from the potential approval of ersodetug as a new treatment option.
• Shareholders may see the continued development and potential approval of ersodetug as a positive indicator for the company's future prospects, despite the primary endpoint miss.

Next Steps

• Submit broader study data to the FDA for comprehensive evaluation.
• Seek alignment with the FDA on an acceptable path to approval for ersodetug in congenital hyperinsulinism.

Key Dates

Recommendation

The recommendation is 'hold' due to the mixed results. While the primary endpoint was not met, the company is presenting compelling secondary and OLE data and has engaged with the FDA, suggesting potential for future approval. However, the lack of statistical significance on the primary endpoint introduces considerable uncertainty.

Keywords

Congenital Hyperinsulinism, Ersodetug, Rezolute, Phase 3 Study, sunRIZE Study, Pediatric Endocrine Society, CGM, Hypoglycemia